Intensive Care Medicine

, Volume 30, Issue 4, pp 580–588 | Cite as

EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units

  • The EPISEPSIS Study GroupEmail author



Ten years ago 8.4% of patients in French intensive care units (ICUs) were found to have severe sepsis or shock and 56% died in the hospital. As novel therapies for severe sepsis are emerging, updated epidemiological information is required.

Design and setting

An inception cohort study conducted in 206 ICUs of randomly selected hospitals over a 2-week period in 2001, including all patients meeting criteria for clinically or microbiologically documented severe sepsis (with ≥1 organ dysfunction).

Measurements and results

Among 3738 admissions, 546 (14.6%) patients experienced severe sepsis or shock, of which 30% were ICU-acquired. The median age of patients was 65 years, and 54.1% had at least one chronic organ system dysfunction. The median (range) Simplified Acute Physiology Score (SAPS II) and Sequential Organ Failure Assessment (SOFA) at onset of severe sepsis were 48 (2–129) and 9 (1–24), respectively. Mortality was 35% at 30 days; at 2 months the mortality rate was 41.9%, and 11.4% of patients remained hospitalized. The median (range) hospital stay was 25 (0–112) days in survivors and 7 (0–90) days in non-survivors. Chronic liver and heart failure, acute renal failure and shock, SAPS II at onset of severe sepsis and 24-h total SOFA scores were the independent risk factors most strongly associated with death.


Although the attack rate of severe sepsis in French ICUs appears to have increased over the past decade, its associated mortality has decreased, suggesting improved management of patients. Severe sepsis incurs considerable resources use, and implementation of effective management strategies and continued research efforts are needed.


Sepsis Cohort studies Epidemiology Prognosis Organ failure 



The EPISEPSIS Study Group is indebted to S. Lancrenon, MSc, and C. Rousseau, MSc, (Sylia-Stat, Bourg-la-Reine, France) for data management and analysis. This study was supported by an unrestricted grant from Lilly-France.

Supplementary material

supp.pdf (73 kb)
Supplementary material (PDF 75 KB)


  1. 1.
    Bone RC, Balk RA, Cerra FB, Dellinger EP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, the ACCP/SCCM Consensus Conference Committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101:1656–1662PubMedGoogle Scholar
  2. 2.
    Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, Boulmé R, Lepage E, Le Gall JR (2002) Epidemiology of sepsis and infection in ICU patients from an international multicenter cohort study. Intensive Care Med 28:108–121 (Erratum p 526)PubMedGoogle Scholar
  3. 3.
    Angus DC, Wax RS (2001) Epidemiology of sepsis: an update. Crit Care Med 29:S109–S116Google Scholar
  4. 4.
    Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Régnier B (1995) Incidence, risk factors and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. JAMA 274:968–974PubMedGoogle Scholar
  5. 5.
    Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM (1999) The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 27:1760–1767Google Scholar
  6. 6.
    Salvo I, de Cian W, Musico M, Langer M, Piadena R, Wolfler A, Montant C, Magni E, the Sepsis Study Group (1995) The Italian SEPSIS study: Preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 21:S244–S249PubMedGoogle Scholar
  7. 7.
    Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS et al. (1997) Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 277:234–240Google Scholar
  8. 8.
    Wichmann MW, Inthorn D, Andress HJ, Schildberg FW (2000) Incidence and mortality of severe sepsis in surgical intensive care patients: the influence of patient gender on disease process and outcome. Intensive Care Med 26:167–172CrossRefPubMedGoogle Scholar
  9. 9.
    Brun-Buisson C (2000) The epidemiology of the systemic inflammatory response. Intensive Care Med 26:S64–S74PubMedGoogle Scholar
  10. 10.
    Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348:1546–1554CrossRefPubMedGoogle Scholar
  11. 11.
    Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 29:1303–1310PubMedGoogle Scholar
  12. 12.
    Le Gall JR, Lemeshow S, Leleu G, Klar J, Huillard J, Rué M, Teres D, Artigas A, The ICU Scoring Group (1995) Customized probability models for early severe sepsis in adult intensive care patients. JAMA 273:644–650PubMedGoogle Scholar
  13. 13.
    Rangel-Frausto MS, Pittet D, Costigan MD, Hwang T, Davis CS, Wenzel RP (1995) The natural history of the systemic inflammatory response syndrome. JAMA 273:117–123PubMedGoogle Scholar
  14. 14.
    Alberti C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R, Smithies M, Thomas O, Artigas A, Le Gall JR (2003) Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 168:77–84CrossRefPubMedGoogle Scholar
  15. 15.
    Brun-Buisson C, Doyon F, Carlet J (1996) Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. Am J Respir Crit Care Med 154:617–624PubMedGoogle Scholar
  16. 16.
    Safdar N, Maki DG (2002) The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile and Candida. Ann Intern Med 136:834–844PubMedGoogle Scholar
  17. 17.
    Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troche G, Chaumet-Riffaut P, Bellissant E (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871PubMedGoogle Scholar
  18. 18.
    Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut J-F, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedGoogle Scholar
  19. 19.
    Kreger BE, Craven DE, Carling P, McCabe WR (1980) Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 68:332–343PubMedGoogle Scholar
  20. 20.
    Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European-North American multicenter study. JAMA 270:2957–2963PubMedGoogle Scholar
  21. 21.
    Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26:1793–1800PubMedGoogle Scholar
  22. 22.
    Friedman G, Silva E, Vincent JL (1998) Has the mortality of septic shock changed with time? Crit Care Med 26:2078–2086PubMedGoogle Scholar
  23. 23.
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345:1368–1377PubMedGoogle Scholar
  24. 24.
    Cohen J, Guyatt G, Bernard GR, Calandra T, Cook DJ, Elbourne D, Marshall J, Nunn A, Opal SM (2001) New strategies for clinical trials in patients with sepsis and septic shock. Crit Care Med 29:880–886Google Scholar
  25. 25.
    Dhainaut JF, Laterre PF, Janes JM, Bernard GR, Artigas A, Bakker J, Riess H, Basson BR, Charpentier J, Utterback BG, Vincent JL (2003) Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29:894–903PubMedGoogle Scholar
  26. 26.
    Pittet D, Thiévent B, Wenzel RP, Li N, Auckenthaler R, Suter PM, Thievent B (1996) Bedside prediction of mortality from bacteremic sepsis. A dynamic analysis of ICU patients. Am J Respir Crit Care Med 153:684–693Google Scholar
  27. 27.
    Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson WJ, Hudson L, Schein R, Summer W, Wright P, Walley KR (2000) Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med 28:3405–3411CrossRefPubMedGoogle Scholar
  28. 28.
    Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL (2001) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758PubMedGoogle Scholar
  29. 29.
    Timsit JF, Fosse JP, Troche G, De Lassence A, Alberti C, Garrouste-Org, Azoulay E, Chevret S, Moine P, Cohen Y (2001) Accuracy of a composite score using daily SAPS II and LOD scores for predicting hospital mortality in ICU patients hospitalized for more than 72 h. Intensive Care Med 27:1012–1021PubMedGoogle Scholar
  30. 30.
    Gross PA, Stein MR, van Antwerpen C, DeMauro PJ, Boscamp JR, Hess W, Wallenstein S (1991) Comparison of severity of illness indicators in an intensive care unit. Arch Intern Med 151:2201–2205CrossRefPubMedGoogle Scholar
  31. 31.
    Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR (2003) Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 31:12–19CrossRefPubMedGoogle Scholar
  32. 32.
    Knaus WA, Harrel FE, Fisher CJ, Wagner DP, Opal SM, Sadoff JC, Draper EA, Walawander CA, Conboy K, Grasela TH (1993) The clinical evaluation of new drugs for sepsis: a prospective study design based on survival analysis. JAMA 270:1233–1241CrossRefPubMedGoogle Scholar
  33. 33.
    Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Crit Care Med 31:1250–1256PubMedGoogle Scholar
  34. 34.
    Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K (2003) Epidemiology of severe sepsis occurring in the first 24 h in intensive care units in England, Wales and Northern Ireland. Crit Care Med 31:2332–2338CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  1. 1.Corresponding author: Christian Brun-Buisson, Service de Réanimation Médicale, CHU Henri MondorAssistance Publique-Hôpitaux de Paris et Université Paris 12CréteilFrance

Personalised recommendations